Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV3 | Q8NET8 | 2/20 | 0.42 |
| ▸ | DGAT2 | Q96PD7 | 2/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.40 |
| ▸ | MAPK3 | P27361 | 3/20 | 0.40 |
| ▸ | PAK4 | O96013 | 1/20 | 0.39 |
| ▸ | NPR1 | P16066 | 5/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.38 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4339892 | 0.92 | ROCK2 (0.44) | TRPV3DGAT2ROCK2ROCK1MAPK1 | |
| SCHEMBL4339186 | 0.89 | NTRK1 (0.41) | TRPV3DGAT2ROCK2ROCK1PAK4 | |
| SCHEMBL4334123 | 0.88 | ROCK2 (0.43) | ROCK2ROCK1MAPK1MAPK3MAP2K4 | |
| SCHEMBL4346841 | 0.87 | ROCK1 (0.41) | ROCK2ROCK1MAPK1MAPK3GABRA5 | |
| SCHEMBL4343384 | 0.87 | MAPK1 (0.39) | TRPV3DGAT2ROCK2ROCK1MAPK1 | |
| SCHEMBL2859833 | 0.85 | MAPK1 (0.54) | DGAT2MAPK1MAPK3 | |
| SCHEMBL27558580 | 0.85 | MAPK1 (0.54) | DGAT2MAPK1MAPK3 | |
| SCHEMBL4334510 | 0.84 | MAPK1 (0.39) | ROCK2ROCK1MAPK1MAPK3GABRA5 | |
| SCHEMBL4338629 | 0.83 | MAPK1 (0.55) | ROCK2ROCK1MAPK1MAPK3PAK4 | |
| SCHEMBL4341423 | 0.82 | ROCK1 (0.39) | ROCK2ROCK1MAPK1MAPK3MAP2K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776890-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| US-7776890-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| US-20090203691-A1 | Novel 1H-indazole compounds | OINUMA HITOSHI | 2009-08-13 | — | — | US | disclosed |
| US-20090203691-A1 | Novel 1H-indazole compounds | OINUMA HITOSHI | 2009-08-13 | — | — | US | disclosed |
| US-7541376-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-02 | — | — | US | disclosed |
| US-20050282880-A1 | Novel 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203691-A1 | Novel 1H-indazole compounds | MAPK1, MAPK3, MAPK13 | TRPV3 394/4885DGAT2 3122/4885ROCK2 805/4885 |
| US-20050282880-A1 | Novel 1H-indazole compounds | MAPK1, MAPK3, MAPK13 | TRPV3 394/4885DGAT2 3122/4885ROCK2 805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.